EARLY, DEEP AND DURABLE RESPONSES WITH CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA
The phase Ib/II CARTITUDE-1 study aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with multiple myeloma. Results demonstrated that a single cilta-cel infusion at the target dose of 0.75 x 106 CAR-positive viable T-cells per kg lead to early, deep and durable responses with a manageable safety profile.
IMPAIRED RESPONSES TO COVID-19 VACCINATION IN PATIENTS WITH LYMPHOMA RECEIVING B-CELL–DIRECTED THERAPIES
As treatment with B-cell-directed therapies may adversely affect the production of antibodies in response to COVID-19 vaccination, it is highly likely that patients treated with these drugs have impaired humoral responses to vaccination. However, results from a recent study now indicated that COVID-19 vaccination at least 9 months from the last B-cell-directed treatment may result in improved antibody titers for lymphoma patients.
GENETIC IDENTIFICATION OF OLDER AML PATIENTS ACHIEVING LONG-TERM SURVIVAL WITH INTENSIVE CHEMOTHERAPY
In order to design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukaemia (AML) of at least 60 years of age treated with intensive ‘7+3’ chemotherapy, 37 genes in 471 patients from the ALFA1200 study were sequenced. Overall, mutations in 7 genes independently predicted overall survival in distinct cytogenetic risk groups of patients.
IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Results from the HOVON-143 trial demonstrate that treatment with ixazomib, daratumumab and low-dose dexamethasone leads to a high response rate and improved quality of life in frail patients with newly diagnosed multiple myeloma. However, treatment discontinuation because of toxicity and early mortality, remain a concern in this frail patient population.
VENETOCLAX COMBINED WITH FLAG-IDA INDUCTION AND CONSOLIDATION IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY AML
Sixty percent of newly diagnosed patients with acute myeloid leukaemia (ND-AML) receiving frontline therapy attain a complete response, yet 30-40% of patients relapse. Recent study results demonstrated that FLAG-IDA plus venetoclax represents an effective intensive induction regimen for ND-AML and relapsed/refractory AML (R/R-AML), with particular utility as a bridge to allogeneic stem cell transplantation in the R/R-AML population.
Top
